Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Serges P Tsofack, Danielle C Croucher, Benjamin G Barwick, Zhihua Li, Ahmed Aman, Dennis Tao, Ellen nong Wei, Laura Garcia Prat, Aaron D Schimmer, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 722.

https://doi.org/10.1182/blood-2021-148673

Published: 2021

Journal Articles

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Danielle C Croucher, Laura M Richards, Zhihua Li, Ellen nong Wei, Xian Fang Huang, Daniel Waller, Marta Chesi, P. Leif Bergsagel, Michael Sebag, Trevor J. Pugh, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2021-151242

Published: 2021

Journal Articles

PIK-001 a Novel Small Molecule Inhibitor of Pikfyve for Treatment of Multiple Myeloma (MM)

A. Keith Stewart, Zhihua Li, Olga Issakova, Nikolai Sepetov, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2021-151208

Published: 2021

Journal Articles

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

Danielle C Croucher, MSc, Marta Chesi, PhD, Zhihua Li, Victoria Marie Garbitt, BS, Meaghen E Sharik, BS, Daniel Waller, PhD, Michael Sebag, MD PhD, P. Leif Bergsagel, MD, Trevor J. Pugh, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2018) 132 (Supplement 1): 56.

https://doi.org/10.1182/blood-2018-99-118691

Published: 2018

Journal Articles

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, Darrell White, MD, Martin Gyger, MD, Jonahtan Kaufmann, MD, Andrzej Jakubowiak, MD PhD, Engin Gul, BSc, Lisa W Le, MSc, Zhihua Li, Donna Reece, Vishal Kukreti, MD FRCPC, Richard LeBlanc

Blood (2015) 126 (23): 4234.

https://doi.org/10.1182/blood.V126.23.4234.4234

Published: 2015

Journal Articles

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Danielle C Croucher, MSc, BSc, Zhihua Li, Brent D.G. Page, PhD, Ellen Nong Wei, Patrick T. Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4441.

https://doi.org/10.1182/blood.V122.21.4441.4441

Published: 2013

Journal Articles

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Blood (2013) 122 (21): 1988.

https://doi.org/10.1182/blood.V122.21.1988.1988

Published: 2013

Journal Articles

Here Is the Sub-Title:Apoptosis on Multiple Myeloma U266 Cell by Phosphorylation c-Jun of Brucine

Yanping Ma, Zhihua Li, Yihua Wang, Jing Feng

Blood (2011) 118 (21): 5112.

https://doi.org/10.1182/blood.V118.21.5112.5112

Published: 2011

Journal Articles

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

James W. Clendening, Aleksandra Pandyra, Zhihua Li, Paul C. Boutros, Anna Martirosyan, Richard Lehner, Igor Jurisica, Suzanne Trudel, Linda Z. Penn

Blood (2010) 115 (23): 4787–4797.

https://doi.org/10.1182/blood-2009-07-230508

Published: 2010

Includes: Supplemental data

Journal Articles

Diagnostic Evaluation of t[4;14] in Multiple Myeloma.

Keith Stewart, Suzanne Trudel, Hong Chang, Kenneth C. Anderson, Paul Richardson, Melissa Alsina, Donna E. Reece, Philip Greipp, Steven Young, Alicia Sable-Hunt, ZhiHua Li, Jonathon Keats, Scott Van Wier, Gregory Ahmann, Tammy Price-Troska, Kathy Giusti, Rafael Fonseca

Blood (2006) 108 (11): 3501.

https://doi.org/10.1182/blood.V108.11.3501.3501

Published: 2006

Journal Articles

MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

Esther Masih-Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart

Blood (2006) 108 (10): 3465–3471.

https://doi.org/10.1182/blood-2006-04-017087

Published: 2006

Includes: Supplemental data

Journal Articles

Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.

Esther Masih-Khan, Suzanne Trudel, MD, ZhiHua Li, Vincent Nadeem, Ellen Wei, Joshua Paterson, Jaime O. Claudio, A. Keith Stewart, MD

Blood (2005) 106 (11): 251.

https://doi.org/10.1182/blood.V106.11.251.251

Published: 2005

Journal Articles

Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.

Ding-Yan Wang, PhD, Xiao-Yan Wen, PhD, Bo Gao, PhD, Gillian Sleep, BSc, Lihua Zhuang, PhD, Chang-Xin Shi, PhD, Zhihua Li, MD, Yi Zhao, MD, Hui Deng, BSc, Nadine Mbuyi, BSc, Tian-Ru Jin, PhD, Joseph Cheung, BSc, A. Keith Stewart, MD

Blood (2004) 104 (11): 4194.

https://doi.org/10.1182/blood.V104.11.4194.4194

Published: 2004

Journal Articles

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

Zhihua Li, Yuan Xiao Zhu, Elizabeth E. Plowright, P. Leif Bergsagel, Marta Chesi, Bruce Patterson, Teresa S. Hawley, Robert G. Hawley, A. Keith Stewart

Blood (2001) 97 (8): 2413–2419.

https://doi.org/10.1182/blood.V97.8.2413

Published: 2001

Journal Articles

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis

Elizabeth E. Plowright, Zhihua Li, P. Leif Bergsagel, Marta Chesi, Dwayne L. Barber, Donald R. Branch, Robert G. Hawley, A. Keith Stewart

Blood (2000) 95 (3): 992–998.

https://doi.org/10.1182/blood.V95.3.992.003k29_992_998

Published: 2000

NARROW

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

PIK-001 a Novel Small Molecule Inhibitor of Pikfyve for Treatment of Multiple Myeloma (MM)

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Here Is the Sub-Title:Apoptosis on Multiple Myeloma U266 Cell by Phosphorylation c-Jun of Brucine

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

Diagnostic Evaluation of t[4;14] in Multiple Myeloma.

MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.

Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only